April 1, 2024
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2023 Financial Results
March 28, 2024
Xilio Therapeutics Announces $11.3 Million Private Placement Equity Financing
March 28, 2024
Gilead and Xilio Announce Exclusive License Agreement for Tumor-Activated IL-12 Program
February 28, 2024
Xilio Therapeutics to Participate in Novel Immuno-Oncology Panel at TD Cowen 44th Annual Health Care Conference
January 31, 2024
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference
January 8, 2024
Xilio Therapeutics Highlights Recent Advances Across Clinical Pipeline and Encouraging Preliminary Phase 1 Safety Data for XTX301, a Tumor-Activated IL-12, Further Validating the Promise of Its Tumor-Activated Immuno-Oncology Therapies